论文部分内容阅读
诺华公司数周前收到了ＦＤＡ发给的一封不能批准其正在研制的一种治疗肠应激综合征 (ＩＢＳ)的药品替加色罗 (ｔｅｇａｓｅｒｏｄ)的信 ,要求该公司提供关于对正在服用该药的患者施行腹部外科手术 (特别是胆囊手术 )的情况的补充资料。在此之前 ,由于替加色罗的疗效未取得欧洲
Novartis received a letter from the FDA a few weeks ago that it could not approve a tegaserod drug it is developing that treats irritable bowel syndrome (IBS) and asked the company to provide a letter about being taken Patients with this medicine will be supplemented with information on abdominal surgery (especially gall bladder surgery). Prior to this, due to the efficacy of tegaserod Europe has not been achieved